• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial

byJames RoebkerandShaidah Deghan, MSc. MD
October 13, 2016
in Oncology, Surgery, Urology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Patients undergoing prostatectomy for prostate cancer had significantly worse self-reported urinary and sexual function compared to radiotherapy and active monitoring, whereas those undergoing radiation therapy had significantly worse bowel function.

2. No significant differences were found between measures of general health between the three treatment options.

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Management of prostate cancer based on prostate-specific antigen (PSA) levels is a controversial issue in men’s health. Early detection and treatment may provide individual and population health benefits, but current treatment options have a significant negative impact on a patient’s quality of life.

The ProtecT trial compared the effectiveness and health outcomes between the three most common current treatments – prostatectomy, radiotherapy, and active monitoring. The primary outcome was mortality which was reported elsewhere. This study reports the secondary outcome of interest – patient-reported outcomes – including measures of urinary, sexual, and bowel function, as well as measures of general health. Prostatectomy was found to have the greatest negative effect on urinary and sexual function, while radiotherapy had the greatest negative effect on bowel function. No significant differences between treatments were found in measures of general health. In conjunction with mortality data provided in the companion study, this provides an appreciation of the risk-benefit tradeoff in managing patients with prostate cancer.

This was a large, randomized trial that used validated patient-reported outcomes and had high response rates. This trial was also used in a larger trial evaluating the effectiveness of PSA for prostate cancer screening, increasing its generalizability. Significant limitations include poor representation of nonwhite males and the introduction of new diagnostic and therapeutic techniques since the trial’s inception.

Click to read the study, published today in NEJM

RELATED REPORTS

Abiraterone plus prednisone improves survival in patients with de novo metastatic castration-sensitive prostate cancer

#VisualAbstract: Bone mineral density testing beneficial for older men receiving androgen deprivation therapy for localized or regional prostate cancer

Darolutamide improves overall survival in patients with hormone-sensitive prostate cancer

Relevant Reading: 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer

In-Depth [randomized controlled trial]: In this randomized trial, population-based PSA screening identified 1643 men with localized prostate cancer that were randomized to active-monitoring (n = 545), radical prostatectomy (n = 553), or radiotherapy (n = 545). The primary outcome (mortality due to prostate cancer or treatment at 10 years), evaluated in a separate analysis, found low levels of death due to prostate cancer (1%) irrespective of treatment, but reported a significantly lower rate of disease progression in the prostatectomy and radiotherapy groups compared to active monitoring (p < 0.001).

The secondary outcome of interest (patient-reported outcomes) described in this study used validated questionnaires based on four domains – urinary function, sexual function, bowel function, and health-related quality of life. Questionnaires were completed at baseline, 6 months and 12 months, and then annually for the 6 years of follow-up. At all time points, prostatectomy had a greatest negative effect on urinary continence (p < 0.001) and erectile function (p < 0.001). In the prostatectomy, radiotherapy, and active monitoring groups, respectively, the rate of absorbent pad use was 17%, 4%, and 8% at 6 months. Sexual function (based on erection firmness and sexual function scores) was reduced from 67% at baseline to 12%, 22%, and 52%, respectively. Bowel function (based on loose and bloody stool reports) was significantly reduced in the radiotherapy group compared to the other treatments (p < 0.001). No significant differences in health-related quality of life measures were found at any time point.

Image: CC/Wiki

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

Tags: prostate cancer
Previous Post

New imaging technology can visualize cancer cells in patients [PreClinical]

Next Post

Advent of mammography associated with increased detection of smaller breast tumors

RelatedReports

Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial
Chronic Disease

Abiraterone plus prednisone improves survival in patients with de novo metastatic castration-sensitive prostate cancer

May 11, 2022
#VisualAbstract: Daprodustat noninferior to darbepoetin alfa in the treatment of anemia in patients with chronic kidney disease on incident dialysis
StudyGraphics

#VisualAbstract: Bone mineral density testing beneficial for older men receiving androgen deprivation therapy for localized or regional prostate cancer

April 13, 2022
Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial
Chronic Disease

Darolutamide improves overall survival in patients with hormone-sensitive prostate cancer

March 28, 2022
#VisualAbstract: Abiraterone acetate improves survival in high-risk non-metastatic prostate cancer compared to control
StudyGraphics

#VisualAbstract: Abiraterone acetate improves survival in high-risk non-metastatic prostate cancer compared to control

February 16, 2022
Next Post
Spiculation of breast masses seen on mammography represents adipose invasion

Advent of mammography associated with increased detection of smaller breast tumors

Non-invasive prenatal testing linked to decreased diagnostic testing

Improving heat-shock protein levels shows efficacy against lysosomal storage diseases [PreClinical]

Paternal involvement in early childhood linked to improved developmental outcomes

Similar prostate cancer mortality with surgery, radiation, and active surveillance: The ProtecT trial

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
  • Wellness Check: Mental Health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.